<DOC>
	<DOCNO>NCT00534469</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy autologous stem cell transplant stop growth cancer cell stop divide kill . After treatment , stem cell collect patient 's blood and/or bone marrow store . More chemotherapy radiation therapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy radiation therapy . Giving aldesleukin transplant may help keep cancer cell come back transplant . PURPOSE : This phase II trial study side effect well give busulfan etoposide together total-body irradiation follow autologous stem cell transplant aldesleukin work treat patient acute myeloid leukemia first remission .</brief_summary>
	<brief_title>Busulfan , Etoposide , Total-Body Irradiation Followed Autologous Stem Cell Transplant Aldesleukin Treating Patients With Acute Myeloid Leukemia First Remission</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate efficacy toxicity preparative regimen comprise busulfan , etoposide , fractionate total-body irradiation follow autologous stem cell transplantation aldesleukin treatment consolidation therapy comprise high-dose cytarabine without idarubicin patient acute myeloid leukemia first remission . - To estimate long-term disease-free survival patient treat regimen . - To evaluate effect prognostic factor ( e.g. , cytogenetics , WBC presentation , number course induction therapy require achieve remission ) outcome autologous stem cell transplantation target busulfan dose . OUTLINE : - Consolidation therapy : Patients receive prior consolidation therapy evaluate determine need additional consolidation therapy . Patients receive prior consolidation therapy receive high-dose cytarabine IV 3 hour every 12 hour day 1-4 idarubicin* IV 5-10 minute day 1-3 . NOTE : *Patients good risk cytogenetics ( 8 ; 21 ) , inv ( 16 ) , ( 16 ; 16 ) patient receive &gt; 200 mg/m² anthracycline receive idarubicin . - Stem cell collection : All patient receive filgrastim ( G-CSF ) IV subcutaneously ( SC ) twice daily begin 7 day completion high-dose cytarabine continue peripheral blood stem cell ( PBSC ) collection complete . Patients adequate number PBSCs collect also undergo bone marrow collection . - Preparative regimen : Patients receive busulfan IV 2 hour day -13 -11 -7 etoposide IV day -2 . Patients also undergo fractionate total-body irradiation day -6 -3 total 8-10 fraction . - Autologous stem cell transplantation : Patients undergo autologous stem cell transplantation use PBSCs ( without bone marrow ) day 0 . Patients receive G-CSF IV SC daily begin day 5 continue blood count recover . - Interleukin therapy : Within 100 day post-transplantation , patient receive aldesleukin IV continuously day 1-4 9-18 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) FAB type M02 M4M7 No M3 disease In first complete hematological remission confirm marrow aspiration biopsy No cytogenetic abnormality remission marrow In complete remission le 6 month Patients complete remission 6 month may eligible upon approval principal investigator No prior myeloproliferative disorder ( e.g. , chronic myeloid leukemia , myelofibrosis , essential thrombocytosis , polycythemia vera ) No prior myelodysplasia secondary leukemia PATIENT CHARACTERISTICS : FEV_1 &gt; 60 % DLCO &gt; 50 % Cardiac ejection fraction ≥ 50 % Creatinine clearance &gt; 60 mL/min No severe chronic medical psychological illness , judgement principal investigator , would jeopardize ability patient tolerate aggressive chemotherapy No HIV positivity Not pregnant Negative pregnancy test PRIOR CONCURRENT THERAPY : Prior consolidation therapy allow No concurrent use follow medication aldesleukin therapy : Corticosteroids ( include blood product `` premeds '' ) Pentoxifylline IV intrathecal methotrexate IV immunoglobulin Other cytokine growth factor</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
</DOC>